Live Breaking News & Updates on Ferdinandos skoulidis

Stay updated with breaking news from Ferdinandos skoulidis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Postdoctoral Fellow – Thoracic and Head & Neck Medical Oncology job with The University of Texas MD Anderson Cancer Center

Postdoctoral Fellow – Thoracic and Head & Neck Medical Oncology job in Houston, Texas (US) with The University of Texas MD Anderson Cancer Center. Apply Today. ....

Houston , Texas , United-states , State-of-texas , Ferdinandos-skoulidis , Health-savings , University-of-texas-md-anderson-cancer-center , Postdoctoral-fellow , Neck-medical-oncology , Cancer-center , Education-vacation , Retirement-system

NIVO/IPI Combo Demonstrates Long-Term Efficacy in NSCLC

After 6 years, previous tumor response, tumor burden reduction, and baseline health-related quality of life all correlated with overall survival. ....

Texas , United-states , Bristol-myers-sqiubb , Calithera-biosciences , Solange-peters , Lausanne-switzerland-university-hospital , National-center , Guardant-health , Pfizer , Bristol-myers-squibb , Boehringer-ingelheim , Novartis

Sotorasib Provides Consistent Clinical Benefit Over Docetaxel in Key Co-Alteration Subgroups of KRAS G12C+ NSCLC

Sotorasib provided consistent benefit over docetaxel in the majority of key prespecified molecularly defined subsets of patients with pretreated KRAS G12C–mutated non–small cell lung cancer enrolled to the phase 3 CodeBreaK 200 trial. ....

Texas , United-states , Houston , Sotorasib-lumakras , Ferdinandos-skoulidis , Amgen , Department-of-thoracic-head , University-of-texas-md-anderson-cancer-center , Neck-medical-oncology , Cancer-center , Sotorasib , Udocetaxel

Dr Skoulidis on the Methods of Analyzing KRAS G12C Inhibitor Efficacy in NSCLC

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the methods utilized in a retrospective study that investigated molecular determinants of KRAS G12C inhibitor efficacy in patients with advanced non–small cell lung cancer.
....

Texas , United-states , Ferdinandos-skoulidis , University-of-texas-md-anderson-cancer-center , Department-of-thoracic-head , Neck-medical-oncology , Cancer-center , The-university-of-texas-md-anderson-cancer-center , Onclive-tv , Lung-cancer ,

Dr Skoulidis on Determinants of KRAS G12C Inhibitor Efficacy in NSCLC

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses molecular determinants of KRAS G12C inhibitor efficacy in advanced non–small cell lung cancer.
....

Texas , United-states , Ferdinandos-skoulidis , Department-of-thoracic-head , University-of-texas-md-anderson-cancer-center , Neck-medical-oncology , Cancer-center , The-university-of-texas-md-anderson-cancer-center , Onclive-tv , Ung-cancer ,